Sudeep Pharma LimitedQ2 FY27 Results & Financial Update
Sudeep Pharma Limited: Q2 FY27 consolidated results and company financials – revenue ₹196.70 Cr, PAT ₹51.81 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Sudeep Pharma price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Sudeep Pharma Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Sudeep Pharma Limited achieved its highest-ever quarterly performance in Q2 FY27, driven by robust demand across its Pharma, Food & Nutrition (PFN) and Specialty Ingredients segments.
Operational efficiency and a favorable product mix enabled strong sequential profitability growth, with profit after tax rising significantly over the previous quarter.
Management reported that the value-added portfolio, particularly AbsorBis, sustained strong growth momentum supported by new customer additions and ongoing regulatory approvals for products such as Magnesium Bisglycinate.
A significant operational milestone during the quarter was the receipt of US FDA approval for the Nandesari greenfield facility, which features an annual capacity of 51,200 metric tonnes, with commercial supplies slated to commence in H2 FY27.
Concurrently, the Dahej Phase 1 battery-grade iron phosphate facility (25,000 MTPA capacity) is progressing on schedule toward a March 2027 completion target and April 2027 commercial operations.
Nutrition Supplies Services (NSS) secured approvals from five customers and maintained an active pipeline of approximately 12 projects as it works to build its growth trajectory for FY28.
01 · Business model
What does Sudeep Pharma do?
Sudeep Pharma Limited is a technology-led specialty ingredients manufacturer founded in 1989, specializing in mineral chemistries, pharmaceutical excipients, food and nutrition ingredients, and advanced battery materials.
The company operates through five manufacturing locations and serves over 1,120 customers globally across approximately 100 countries, supplying critical functional components such as mineral fortificants, excipients, and nutritional premixes.
Sudeep's product portfolio addresses high-barrier application segments including pharmaceuticals, infant nutrition, functional foods, sports nutrition, and lithium-ion battery supply chains through its subsidiary Sudeep Advanced Materials Private Limited.
02 · Historical context
What shaped the business before this quarter
Sudeep Pharma was founded in 1989, starting operations with an acquired unit in Nandesari GIDC, Vadodara, and manufacturing calcium excipients for pharmaceutical applications.
Sudeep bought back its stake from JRS Pharma and diversified into sustainable battery materials through Sudeep Advanced Materials Private Limited (SAMPL).
The company acquired an 85% stake in Nutrition Supplies Services (NSS) in May 2025, expanding its capabilities in vitamin and mineral dry/liquid blends for infant nutrition and critical care.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹196.70 Cr | ₹158.27 Cr |
| Total income | ₹202.68 Cr | ₹163.72 Cr |
| Profit before tax | ₹71.03 Cr | ₹54.29 Cr |
| Profit after tax | ₹51.81 Cr | ₹40.59 Cr |
| EPS | ₹4.59 | ₹3.59 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
PFN contributed 72% of total revenue during Q2 FY27, benefiting from healthy demand across key domestic and international markets.
Specialty Ingredients contributed 28% of total revenue, underpinned by traction in value-added offerings like AbsorBis.
Exports accounted for 65% of Q2 FY27 revenue, while domestic markets represented 35%.
What drove margins
EBITDA margin improved to 37.2% in Q2 FY27 (up from 34.1% in Q2 FY26), aided by a favorable product mix and operational efficiencies despite elevated logistics costs.
Cost of materials consumed stood at 69.5 crore INR for Q2 FY27, reflecting stable input cost management relative to scaling top-line revenues.
05 · Demand, customers & order book
Where demand is coming from
Sudeep serves over 1,120 customers globally, including 14 Fortune 500 companies and over 40 blue-chip MNCs, with the top 10 customers accounting for 32% of revenue.
At SAMPL, the company reported 46 active customers, 28 product approvals, 8 signed MOUs, and zero sample rejections for its battery-grade iron phosphate.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Accounted for 72% of Q2 FY27 revenue; benefited from customer additions and regulatory progress in products like Magnesium Bisglycinate.
Contributed 28% of quarterly revenue; includes recent contributions from NSS which began contributing from May 22, 2025.
Geography and market mix
Exports constituted 65% of Q2 FY27 revenue, reflecting deep integration into regulated global pharmaceutical, food, and nutrition supply chains.
Domestic operations contributed 35% of total revenue for the quarter.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Total annual manufacturing capacity stands at 1,48,700 MT for FY27 existing operations across units, including the 51,200 MT greenfield facility at Nandesari.
Phase 1 of the Dahej battery materials plant will add 25,000 MTPA by March 2027, with total planned capacity scaling towards 1,05,000 MTPA.
Projects, capex and execution
The 51,200 MTPA capacity Nandesari greenfield facility involved a total capex of approximately 168 crore INR, financed via internal accruals.
Construction of the Dahej plant for battery-grade iron phosphate is progressing on track with an estimated project cost of approximately 300 crore INR, funded via internal accruals and debt.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Positioning as a non-Chinese supplier for LFP battery cathode active material precursors, complying with US IRA and EU Critical Raw Materials Act regulations.
Integrating the UK/Ireland-based IMF-grade premix manufacturing facility to capture high-care infant nutrition and critical care market share in Europe.
09 · Reported developments
What changed operationally
Received US FDA approval for the Nandesari greenfield facility with an annual capacity of 51,200 MT, opening access to regulated markets.
Achieved highest-ever quarterly EBITDA of 73.2 crore INR in Q2 FY27, representing a 32% YoY growth with margin expansion of ~70 bps YoY to 37.2%.
10 · Pressure points & risks
What is not going smoothly
Management noted ongoing pressures from elevated global logistics costs affecting operational margins.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net working capital days stood at 215 days for H1 FY27, reflecting ongoing requirements in specialty ingredient manufacturing and inventory staging.
Net cash from operating activities for H1 FY27 reached 43.5 crore INR compared to 17.7 crore INR in H1 FY25.
Capital allocation & funding
Consolidated non-current borrowings stood at 62.4 crore INR and current borrowings at 125.2 crore INR as of September 30, 2026.
Net debt to equity remained low, reflecting a disciplined balance sheet structure.
12 · Management guidance & targets
What management is targeting from here
Management targets completion of Phase 1 (25,000 MTPA) of the Dahej battery materials project by March 2027, with commercial operations commencing from April 2027.
Management expects commercial supplies from the newly FDA-approved Nandesari greenfield facility to commence in H2 FY27.
Management targets signing multiple binding offtake agreements for battery-grade materials by Q4 FY27.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
Management Transition
Mr. Sendhil Kumar Pani ceased to be a Senior Management Personnel of the company effective October 2, 2026.
14 · Previous-quarter changes
What changed since the previous quarter
Revenue expanded sequentially from 158.2705 crore INR in Q1 FY27 to 196.6991 crore INR in Q2 FY27.
15 · Key Q&A
The quarter, answered directly
What does Sudeep Pharma do?
Sudeep Pharma Limited is a technology-led specialty ingredients manufacturer founded in 1989, specializing in mineral chemistries, pharmaceutical excipients, food and nutrition ingredients, and advanced battery materials.
What is the clearest takeaway from Q2 FY27?
Sudeep Pharma Limited achieved its highest-ever quarterly performance in Q2 FY27, driven by robust demand across its Pharma, Food & Nutrition (PFN) and Specialty Ingredients segments.
What drove revenue or demand?
PFN contributed 72% of total revenue during Q2 FY27, benefiting from healthy demand across key domestic and international markets.
What mattered most for margins or profitability?
EBITDA margin improved to 37.2% in Q2 FY27 (up from 34.1% in Q2 FY26), aided by a favorable product mix and operational efficiencies despite elevated logistics costs.
What changed operationally beyond the headline numbers?
Total annual manufacturing capacity stands at 1,48,700 MT for FY27 existing operations across units, including the 51,200 MT greenfield facility at Nandesari.
What is management guiding or targeting from here?
Management targets completion of Phase 1 (25,000 MTPA) of the Dahej battery materials project by March 2027, with commercial operations commencing from April 2027.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Nandesari Commercialization: Track the commencement of commercial supplies from the Nandesari greenfield facility in H2 FY27.
- 02
Dahej Plant Execution: Monitor construction milestones and binding offtake agreement announcements for the Dahej battery materials project ahead of its March 2027 completion target.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.